Robert Balk to Survival Analysis
This is a "connection" page, showing publications Robert Balk has written about Survival Analysis.
Connection Strength
0.137
-
Therapeutic use of antithrombin concentrate in sepsis. Semin Thromb Hemost. 1998; 24(2):183-94.
Score: 0.036
-
Multicenter, randomized, placebo-controlled study of the nitric oxide scavenger pyridoxalated hemoglobin polyoxyethylene in distributive shock. Crit Care Med. 2008 Jul; 36(7):1999-2007.
Score: 0.019
-
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med. 2003 Jun; 31(6):1612-9.
Score: 0.013
-
Adenosine deaminase inhibition attenuates microvascular dysfunction and improves survival in sepsis. Am J Respir Crit Care Med. 2002 Jul 01; 166(1):16-20.
Score: 0.012
-
E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA. 2000 Apr 05; 283(13):1723-30.
Score: 0.011
-
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997 Jul; 25(7):1115-24.
Score: 0.009
-
Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996 Jun 27; 334(26):1697-702.
Score: 0.008
-
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med. 1995 Jun; 23(6):994-1006.
Score: 0.008
-
Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995 Mar 22-29; 273(12):934-41.
Score: 0.007
-
Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA. 1994 Nov 09; 272(18):1433-8.
Score: 0.007
-
Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994 Jun 15; 271(23):1836-43.
Score: 0.007